Arcutis (ARQT) news

Oruka Therapeutics appoints Todd Edwards as chief commercial officer

Oruka Therapeutics has appointed L. Todd Edwards as its chief commercial officer (CCO), bringing extensive experience in the commercialization of dermatological and immunological therapies to the company. Edwards, who previously served as CCO at Arcutis Biotherapeutics, Inc., has over 25 years of…

Arcutis BioTherapeutics: raised net product sales guidance for the full year 2026 from $480 million–$495 million to $525 million–$540 million

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has raised its net product sales guidance for the full year 2026, increasing the range from $480 million–$495 million to $525 million–$540 million. This upward revision reflects the company’s strong performance in the first quarter of 2026, during which…

Arcutis Biopharma Q2 EPS USD 0.11

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) reported a net loss of $0.13 per basic and diluted share for the second quarter of 2025, compared to a net loss of $0.42 per share in the same period in 2024. The company’s second-quarter 2025 financial results reflect continued growth in net product…

Arcutis Biotherapeutics - FDA sets PDUFA target action date of February 23, 2027 for Zoryve Cream 0.05% SNDa

Arcutis Biopharma reports inducement grants under Nasdaq listing rule 5635(c)(4)

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has reported the issuance of inducement grants to 40 newly hired employees under its 2022 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4) . On May 1, 2026, the company granted a total of 269,000 restricted stock units and options to…